Development of Novel Therapeutics for Select Pathogens (R21/R33)

 

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support basic to translational research focused on development of novel therapeutics against select antibiotic-resistant gram-negative bacteria or influenza.

Deleted 11/20/2014 (Archived.) RFA-AI-14-026 Agency: Department of Health and Human Services
Office: National Institutes of Health Grant Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign Institutions Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 10/20/2014 This program does not have cost sharing or matching requirements. NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-026.html FBOWebmaster@OD.NIH.GOV $3,100,000.00 Awards up to $300,000.00